ScreenerHero

TCRX TScan Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · tscan.com
0.2769USD+0.54%Mkt Cap: 18.10M $P/E: —

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap18.10M USD
Enterprise Value9.40M USD
Revenue (TTM)7.11M USD
Gross Profit-88.32M USD
Net Income (TTM)-129.77M USD
Revenue/Share0.10 USD
Last Price0.2769 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees138
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.48
PEG—
EV/EBITDA-0.08
EV/Revenue1.32
P/S2.53
P/B0.27
EPS (TTM)-0.85
EPS (Forward)-0.57
52W Range
0.26271% of range2.570
52W High2.570 USD
52W Low0.2627 USD
Profitability
Gross Margin0.00%
Oper. Margin-2901.33%
EBITDA Margin0.00%
Profit Margin-1256.81%
ROE-105.40%
ROA-56.72%
Growth
Revenue Growth-65.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-135.32M USD
CapEx (TTM)4.41M USD
FCF Margin-1123.95%
FCF Yield-441.67%
Net Debt-9.26M USD
Net Debt/EBITDA0.08
Balance Sheet
Debt/Equity0.76
Current Ratio3.37
Quick Ratio3.23
Book Value/Sh1.02 USD
Cash/Share1.48 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.6 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)1.000 USD
Upside (mean)+261.1%
Target Range1.000 USD – 1.000 USD
# Analysts2
Ownership
Shares Out.61.07M
Float54.36M
Insiders0.19%
Institutions67.88%
Short Interest
Short Ratio2.1d
Short % Float4.83%
Short % Out.3.36%
Shares Short2.28M
Short (prev mo.)1.60M
Technical
SMA 500.5668 (-51.2%)
SMA 2000.9304 (-70.2%)
Beta1.14
S&P 52W Chg16.45%
Avg Vol (30d)1.00M
Avg Vol (10d)617.19K
Technical Indicators
RSI (14)23.1
MACD-0.0859
MACD Signal-0.0970
MACD Hist.+0.0112
BB Upper0.3812 USD
BB Middle0.3255 USD
BB Lower0.2697 USD
BB Width34.28%
ATR (14)0.0396 USD
Vol Ratio (20d)0.58x